Basiliximab vs Reduced Dose Rabbit Antithymocyte Globulin (rRTAG): Evaluation of Efficacy and Safety Outcomes in Low Immunological Risk Living Donor Kidney Transplant: 12-month Randomized Controlled Study
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Antithymocyte globulin (Primary) ; Basiliximab
- Indications Graft-versus-host disease; Renal transplant rejection
- Focus Therapeutic Use
- 13 Mar 2020 Primary endpoint has been met. (Biopsy proven acute rejection)
- 13 Mar 2020 Results evaluating difference in infection and adverse event between Low-dose Thymoglobulin vs Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients, published in the Transplantation Proceedings
- 14 Nov 2019 Status changed from active, no longer recruiting to completed.